Imran Mahrukh, Mills Caroline, McDermott Kimberly W, Dean Alex, Bogdanov Alina, McGovern Ian, Haag Mendel
CSL Seqirus, Kirkland, Quebec, Canada.
Veradigm, Chicago, IL, USA.
Vaccine. 2024 Dec 2;42(26):126316. doi: 10.1016/j.vaccine.2024.126316. Epub 2024 Sep 19.
This study estimated the relative vaccine effectiveness (rVE) of the MF59®-adjuvanted trivalent influenza vaccine (aTIV) versus standard-dose nonadjuvanted egg-based quadrivalent influenza vaccines (QIVe) for the prevention of influenza-related medical encounters (IRMEs), outpatient IRMEs, and influenza- and pneumonia-related hospitalizations during the 2019-2020 US influenza season among adults ≥65 years of age who had ≥1 high-risk condition. A secondary objective evaluated the rVE of aTIV versus QIVe in preventing these outcomes among older adults with specific high-risk conditions. This retrospective cohort study included US adults ≥65 years of age vaccinated with aTIV or QIVe between August 1, 2019, and January 31, 2020. Exposures, covariates, risk factors, and outcomes were captured from a linked dataset comprised of electronic health records (EHR) (Veradigm Network EHR) linked to insurance claims (Komodo Healthcare Map). A doubly robust approach was applied wherein multivariable-adjusted odds ratios were derived using inverse probability of treatment-weighted samples to calculate rVEs and 95 % confidence interval independently for individuals ≥1 high-risk condition and those with specific high-risk conditions. The study included 954,707 aTIV and 719,125 QIVe recipients. For all outcomes, aTIV was more effective than QIVe among adults ≥65 years of age who had ≥1 high-risk condition (any IMRE: 23.6 % [20.9 %-26.1 %]), outpatient IRME: 23.3 % [20.4 %-26.1 %], and influenza- or pneumonia-related hospitalizations: 19.0 % [16.3 %-21.6 %]), during the 2019-2020 influenza season. Similarly, aTIV was more effective than QIVe at preventing outcomes among individuals with specific high-risk conditions except for body mass index ≥40. This study demonstrated higher effectiveness of aTIV versus QIVe in preventing any IRMEs, outpatient IRMEs, and influenza- or pneumonia-related hospitalizations among adults ≥65 years of age who had ≥1 high-risk condition.
本研究评估了MF59®佐剂三价流感疫苗（aTIV）与标准剂量非佐剂鸡蛋基四价流感疫苗（QIVe）在预防2019 - 2020年美国流感季节期间≥65岁且患有≥1种高危状况的成年人的流感相关医疗就诊（IRME）、门诊IRME以及流感和肺炎相关住院方面的相对疫苗效力（rVE）。次要目标是评估aTIV与QIVe在预防患有特定高危状况的老年人的这些结局方面的rVE。这项回顾性队列研究纳入了2019年8月1日至2020年1月31日期间接种aTIV或QIVe的≥65岁美国成年人。暴露因素、协变量、风险因素和结局从一个由与保险理赔（Komodo Healthcare地图）相链接的电子健康记录（EHR）（Veradigm网络EHR）组成的关联数据集中获取。应用了双重稳健方法，其中使用治疗加权样本的逆概率独立计算≥1种高危状况个体和患有特定高危状况个体的rVE和95%置信区间，得出多变量调整后的比值比。该研究纳入了954,707名aTIV接种者和719,125名QIVe接种者。对于所有结局，在2019 - 2020年流感季节期间，aTIV在≥65岁且患有≥1种高危状况的成年人中比QIVe更有效（任何IMRE：23.6% [20.9% - 26.1%]），门诊IRME：23.3% [20.4% - 26.1%]，以及流感或肺炎相关住院：19.0% [16.3% - 21.6%]）。同样，除了体重指数≥40的个体外，aTIV在预防患有特定高危状况个体的结局方面比QIVe更有效。这项研究表明，aTIV在预防≥65岁且患有≥1种高危状况的成年人的任何IRME、门诊IRME以及流感或肺炎相关住院方面比QIVe更有效。
